Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (1031)	2/20/2000 4:55:00 PM
From: Bipin Prasad	Read Replies (1) \| Respond to of 4474

ARIAD Shares Now Traded On the Frankfurt Stock Exchange CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 18, 2000--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its shares are being traded on the Regulated Unofficial Market of the Frankfurt Stock Exchange (the Deutsche Borse), beginning as of January 26, 2000. Share prices are quoted in Euros. The Frankfurt Stock Exchange is the world's third largest organized exchange-trading market in terms of turnover and dealings in securities and accounts for more than three quarters of the total securities turnover in Germany. Further information concerning the Exchange and quotations can be obtained on its web site (www.exchange.de). "Trading of ARIAD's securities on the largest exchange in Europe should provide greater liquidity for our investors, especially in the growing European markets for biotechnology and high technology companies," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. ARIAD Pharmaceuticals (www.ariad.com) is engaged in the discovery and development of gene-targeted therapeutics based on signal transduction technology. ARIAD is developing gene therapy products, regulated by small-molecule drugs, for protein and cell therapy based on its proprietary gene regulation and gene activation technologies including the ARGENT(TM) and RAPID(TM) systems. The Company also is developing orally administered small-molecule drugs to block intracellular signaling pathways that play a critical role in major diseases, such as osteoporosis and immune-related disorders. Some of the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, which include, but are not limited to, risks and uncertainties regarding the Company's operations, as well as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on our collaborators and other factors under the heading "Cautionary Statement Regarding Forward-Looking Statements" in ARIAD's Annual Report on Form 10-K for the fiscal year ended December 31, 1998 filed with the Securities and Exchange Commission.